Applied DNA Sciences, Inc. announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™? in under six weeks. The quantity was produced by the Company's LinearDNA™?

platform under a large recurring purchase order with a global manufacturer of in vitro diagnostics that was announced in the first quarter of fiscal 2023 and is the single shipment of linearDNA to date. The Company expects to ship a final multi-gram quantity in the third fiscal quarter of 2023 to fulfill the purchase order earlier than contractually stipulated. The Company's LinearDNA platform is focused on empowering the next generation of nucleic acid-based therapies.

The platform uses a cell-free, enzymatic approach that confers the advantages of simplicity, purity, speed, flexibility, and scalability in a fractional footprint relative to conventional plasmid DNA (fermentation)-based manufacturing processes. The resultant DNA, known as linearDNA™, is currently produced at GLP-grade in volumes from micrograms to grams to support customers' needs. The Company is pursuing a timeline for cGMP linearDNA production that will enable it to support customers from research and development and drug discovery through large-scale manufacturing for clinical trials and commercial use.